Biocardia Inc BCDA

$1.04 +0.02 (1.96%)

Valuation

Market cap
15,442,000
Revenue TTM
$0
Net income TTM
$-8,230,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
52,500
Avg volume
281,040
Day's range
$1.03 – $1.05
Shares out
15,139,000
Stochastic %K
50%
Beta
0.62
Analysts
Sell
Price target
$15.50

Price

Company profile

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic...

Show more

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.

Industry
Biotechnology
Sector
Healthcare
Phone
650 226 0120
Website
https://www.biocardia.com
Address
320 Soquel Way, Sunnyvale, United States

Latest news

Stocktwits

DipBuyInvester Oct 2, 1:22 PM
$BCDA 👀👀👀🚀🚀🚀💪💪💪🔥🔥👀👀
2 replies
Jusme Oct 1, 6:22 PM
$BCDA How Novel Is the Helix? A True Category-Creator BioCardia's CEO stated the goal plainly: this pre-submission "should lead to our Helix catheter being the first approved transendocardial delivery catheter system in the United States." That's the critical framing — not "better than the competition" but the only one of its kind with FDA clearance.
1 replies
Raycloser Oct 1, 3:06 PM
$BCDA I thought this submission news would have moved the stock up
1 replies
50shadesoftrades Oct 1, 1:16 PM
$BCDA $BCDA BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter https://www.stocktitan.net/news/BCDA/bio-cardia-files-revised-de-novo-pre-submission-for-fda-approval-of-2qnd4qzvtmr8.html
0 replies
Jusme Oct 1, 3:06 AM
$BCDA Keep in mind who the majority fund owners are in this company. They will manipulate the pps six ways to Sunday to achieve their returns.
0 replies
CEOBuysDisclosures Oct 1, 12:55 AM
$BCDA CEO purchased 1,000 shares at $1.03 for a total of $1,030. Altman Peter now owns 384,885 shares. https://ceo-buys.com
1 replies
Jusme Sep 30, 2:48 AM
$BCDA Key Observations: 1. The PMDA trigger clause is strategically significant. The April and June 2025 warrants expire upon Japan PMDA approval — meaning those warrant holders are incentivized to exercise before a Japan approval catalyst, not after. That creates natural buying pressure as the PMDA submission approaches. 2. The September 2025 warrants are the biggest block — 4.8 million shares at $1.25, expiring around September 2027. BioCardia explicitly noted that if all currently outstanding warrants are exercised in full for cash, the cash runway would extend well beyond PMDA approval and into first commercial sales. That's a powerful statement — full warrant exercise could essentially fund the company to commercialization without any additional dilutive raises. 3. Potential cash inflow if all warrants exercised: * 4,800,000 × $1.25 = $6.0M * 2,400,000 × $3.00 = $7.2M * 406,818 × $1.905 = $775K * 274,696 × $1.95 = $536K * Total potential proceeds ≈ $14.5M
1 replies
Jusme Sep 30, 2:10 AM
$BCDA Here's the complete warrant picture as of June 30, 2026, compiled from SEC filings: Total Outstanding Warrants: 7,846,514 Weighted average exercise price: $1.84/share Weighted average term remaining: 2.1 years Breakdown by Financing Tranche: Financing Warrants Exercise Price Expiration February 2024 67,104 $6.60 Feb 13, 2026 (expired during H1 2026) September 2024 Registered Offering ~2,400,000 $3.00 September 3, 2029 April 2025 Private Placement 406,818 $1.905 April 24, 2030 or PMDA approval (whichever is earlier) June 2025 Private Placement 274,696 $1.95 June 30, 2030 or PMDA approval (whichever is earlier) September 2025 Public Offering 4,800,000 $1.25 ~September 2027 (2-year term)
0 replies